Novel therapeutic agent for reversing vascular dysfunction in alzheimer's disease - revised project summary : alzheimer's disease (ad) is the most common form of neurodegenerative disorder…
Ended Project Grant Awarded Last action
- Award ID
- R43AG071399
- Recipient
-
Aivocode, Inc. UEI TLPZZJEMNND1
- Awarding agency
-
National Institute on Aging
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,301,682
Award facts
- Assistance listing
- 93.866 Aging Research
- Completion date
- Originally
- Funding
-
- $867,788.00 Federal
- $433,894.00 Non-federal
- Place of performance
- La Jolla, CA 92037, USA
Award details come from USAspending.gov.
Description
Novel therapeutic agent for reversing vascular dysfunction in alzheimer's disease - revised project summary : alzheimer's disease (ad) is the most common form of neurodegenerative disorder associated with aging. One of the hallmarks of this disorder is the progressive loss of neuronal cells, which ultimately becomes fatal. Several lines of investigations implicate the role of vascular dysfunction, characterized by the loss of mural cells (PERICYTES) and compromised blood-brain-barrier, in pathogenesis of ad. Academic collaborators and founders of aivocode INC., the applicant company, have employed unbiased screening with in vivo phage display to probe specific vascular signature present in the brains of transgenic ad mice. This new approach to ad studies has generated a new and understudied therapeutic target that binds extracellular matrices and cell surfaces including brain vasculature in ad mice. In this phase I application, we propose to screen recombinant antibodies against this novel target to neutralize its activity in mouse models of ad to reverse vascular dysfunction and test if IT leads to slower disease progression. The results of this study will serve as stepping-stone for the company to develop a therapeutic candidate for ad.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $433,894 | $0 | |
| Original award | $433,894 | $433,894 |
Quick answers
Who received award R43AG071399?
R43AG071399 was awarded to Aivocode, Inc. by National Institute on Aging (National Institutes of Health) on May 1, 2021.
How much is award R43AG071399 worth?
$1,301,682 has been obligated on R43AG071399: $867,788 in federal funding and $433,894 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award